IGF2BP1 and acute myeloid leukemia: Knockdown of IGF2BP1 results in less colony-forming and higher drug sensitivity to chemotherapeutic drugs, including doxorubicin, cytarabine, and cyclophosphamide in AML cells (Figure 2 and Table 4) (Elcheva et al., 2020).